HONG KONG – Astrazeneca plc has received approval for two drug candidates – PARP inhibitor Lynparza (olaparib) and IL-5 receptor targeting Fasenra (benralizumab) – from the Japanese Ministry of Health, Labour and Welfare, the latest sign of the big pharma's recent improvement in productivity following its 2011 overhaul. Read More
HONG KONG – Taiwan Liposome Co. Ltd. (TLC) has established a joint venture (JV) with China's Jixi Biotechnology Partners dedicated to clinical trials, registration and commercialization of its products in mainland China. Read More
PERTH, Australia – Most multinational pharma companies vehemently opposed the Therapeutic Goods Administration's plan to stick with the status quo in Australia and use a single name for biologics and biosimilars without a specific identifier suffix. Even so, the regulator said it would continue to use its single naming system and beef up its adverse event reporting system. Read More
NEW DELHI – India is looking to reap the benefits of the current global momentum for regenerative medicine, with an anticipated spike in regenerative medicine products in the coming five to eight years, due mainly to the country's bright innovation landscape, both in biotech startups and research institutes. Read More
In a new study, researchers at the U.K.'s University of Liverpool and Johns Hopkins University School of Medicine in Baltimore have jointly developed a new long-acting nanomedicine-based delivery system for preventing malaria. Read More
PERTH, Australia – Australia's Viralytics Ltd. is on its way to completing its phase Ib immunotherapy programs of lead candidate Cavatak following a A$29.6 million (US$23.9 million) private placement earlier this month with China's Lepu Medical Group. Read More
SHANGHAI – EOC Pharmaceutical Group, a specialty pharma with seven cancer assets in its pipeline, has started with the end in mind – not just getting its drugs approved by the CFDA but having them be commercially successful as well. Read More
Sillajen Inc., of Busan, South Korea, and ABL Europe, a subsidiary of ABL Inc., of Rockville, Md., expanded their manufacturing collaboration that currently includes ABL manufacturing Pexa-Vec (JX-594) for Sillajen. The expanded collaboration includes development, manufacturing and quality control release testing services for Sillajen's pipeline product, JX-970. Read More
